ad image

OncoResponse

1 / 1
OncoResponse
Clinical Trials

OncoResponse to Present Phase 1 Results of Clinical Study of OR502, anti-LILRB2 Antibody, as a Late-Breaker Poster

OncoResponse

PR-10-24-NI-73Nov 05, 2024
1 / 1